AR067771A1 - Avidina oxidada que tiene una mayor permanencia en tejidos tratados - Google Patents
Avidina oxidada que tiene una mayor permanencia en tejidos tratadosInfo
- Publication number
- AR067771A1 AR067771A1 ARP080103343A ARP080103343A AR067771A1 AR 067771 A1 AR067771 A1 AR 067771A1 AR P080103343 A ARP080103343 A AR P080103343A AR P080103343 A ARP080103343 A AR P080103343A AR 067771 A1 AR067771 A1 AR 067771A1
- Authority
- AR
- Argentina
- Prior art keywords
- avidin
- oxidation
- oxidized
- periodate
- avidins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen avidinas químicamente modificadas que tienen una mayor permanencia en tejidos tratados, en comparacion con la avidina de tipo silvestre. La oxidacion de la avidina se efectua por incubacion de periodato en presencia del ligando de baja afinidad HABA, que, al ocupar los sitios de union con la biotina, impide la desnaturalizacion de la proteína durante la etapa de oxidacion. La oxidacion de periodato genera grupos CHO de la apertura del anillo de manosa de avidina que, una vez inyectados, reaccionan con residuos de NH2 del tejido y forman bases de Schiff estables. Las avidinas fijadas mantienen la capacidad de ligar agentes biotinilados dotados de actividad terapéutica, como las biotinas radiomarcadas, células madre y células somáticas, utiles para braquiterapias, como la Terapia con Radionucleidos por Avidinacion Intraoperatoria (IART«), o enfermedades degenerativas o genéticas. Reivindicacion 1: Una avidina oxidada, en la cual al menos un residuo de manosa por molécula de avidina es reemplazado por un residuo de la formula (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113733 | 2007-08-02 | ||
| EP08157473 | 2008-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067771A1 true AR067771A1 (es) | 2009-10-21 |
Family
ID=39734214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103343A AR067771A1 (es) | 2007-08-02 | 2008-08-01 | Avidina oxidada que tiene una mayor permanencia en tejidos tratados |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8562947B2 (es) |
| EP (1) | EP2185203B1 (es) |
| JP (1) | JP5577248B2 (es) |
| KR (1) | KR101544628B1 (es) |
| CN (1) | CN101772353B (es) |
| AR (1) | AR067771A1 (es) |
| AU (1) | AU2008281901B2 (es) |
| BR (1) | BRPI0815050B8 (es) |
| CA (1) | CA2694391C (es) |
| DK (1) | DK2185203T3 (es) |
| EA (1) | EA017017B1 (es) |
| ES (1) | ES2625815T3 (es) |
| HK (1) | HK1145290A1 (es) |
| HR (1) | HRP20170735T1 (es) |
| HU (1) | HUE032093T2 (es) |
| IL (1) | IL203321A (es) |
| LT (1) | LT2185203T (es) |
| MX (1) | MX2010001302A (es) |
| MY (1) | MY155347A (es) |
| NZ (1) | NZ582711A (es) |
| PL (1) | PL2185203T3 (es) |
| PT (1) | PT2185203T (es) |
| SG (1) | SG183076A1 (es) |
| SI (1) | SI2185203T1 (es) |
| TW (1) | TWI441650B (es) |
| WO (1) | WO2009016031A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2591524C2 (ru) * | 2010-12-28 | 2016-07-20 | Джапан Тобакко Инк. | Модифицированный тамавидин |
| KR101966630B1 (ko) | 2011-08-02 | 2019-04-09 | 알파시그마 에스.피.에이. | 흡입에 적당한 산화된 아비딘의 약제학적 조성물 |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| JP2016511747A (ja) | 2013-01-04 | 2016-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | ナノ粒子表面結合に基づく薬物の組織への送達 |
| US10925852B2 (en) | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| US20200179530A1 (en) * | 2016-05-19 | 2020-06-11 | University Of Miami | Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells |
| JP7245907B2 (ja) * | 2018-09-25 | 2023-03-24 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 共役分子トラップを使用して、アッセイからビオチン干渉を取り除く方法および組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015979A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US5716594A (en) * | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
| US8021667B2 (en) * | 1994-11-16 | 2011-09-20 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Compositions for immunotherapy and uses thereof |
| US6632929B1 (en) * | 1998-11-10 | 2003-10-14 | Yeda Research And Development Co. Ltd | Avidin derivatives and uses thereof |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US20040101901A1 (en) * | 2002-11-27 | 2004-05-27 | Piotr Tabaczewski | Novel lipophilic complexes for insertion of receptors into lipid membranes |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2008
- 2008-07-16 LT LTEP08775109.5T patent/LT2185203T/lt unknown
- 2008-07-16 NZ NZ582711A patent/NZ582711A/en unknown
- 2008-07-16 EP EP08775109.5A patent/EP2185203B1/en active Active
- 2008-07-16 WO PCT/EP2008/059260 patent/WO2009016031A1/en active Application Filing
- 2008-07-16 SI SI200831808A patent/SI2185203T1/sl unknown
- 2008-07-16 ES ES08775109.5T patent/ES2625815T3/es active Active
- 2008-07-16 MX MX2010001302A patent/MX2010001302A/es active IP Right Grant
- 2008-07-16 EA EA201070216A patent/EA017017B1/ru unknown
- 2008-07-16 AU AU2008281901A patent/AU2008281901B2/en active Active
- 2008-07-16 CN CN2008801016692A patent/CN101772353B/zh active Active
- 2008-07-16 DK DK08775109.5T patent/DK2185203T3/da active
- 2008-07-16 MY MYPI2010000136A patent/MY155347A/en unknown
- 2008-07-16 KR KR1020107004513A patent/KR101544628B1/ko active IP Right Grant
- 2008-07-16 HU HUE08775109A patent/HUE032093T2/en unknown
- 2008-07-16 JP JP2010518601A patent/JP5577248B2/ja active Active
- 2008-07-16 PT PT87751095T patent/PT2185203T/pt unknown
- 2008-07-16 SG SG2012054938A patent/SG183076A1/en unknown
- 2008-07-16 CA CA2694391A patent/CA2694391C/en active Active
- 2008-07-16 US US12/670,925 patent/US8562947B2/en active Active
- 2008-07-16 BR BRPI0815050A patent/BRPI0815050B8/pt active IP Right Grant
- 2008-07-16 PL PL08775109T patent/PL2185203T3/pl unknown
- 2008-07-18 TW TW097127328A patent/TWI441650B/zh active
- 2008-08-01 AR ARP080103343A patent/AR067771A1/es active IP Right Grant
-
2010
- 2010-01-14 IL IL203321A patent/IL203321A/en active IP Right Grant
- 2010-12-16 HK HK10111803.2A patent/HK1145290A1/xx unknown
-
2017
- 2017-05-16 HR HRP20170735TT patent/HRP20170735T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067771A1 (es) | Avidina oxidada que tiene una mayor permanencia en tejidos tratados | |
| PA8627201A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| BRPI0410649A (pt) | benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k | |
| DE602005002562D1 (de) | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel | |
| ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
| BRPI0500704A (pt) | composições de tratamento pessoal reidratáveis | |
| UY28861A1 (es) | Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
| GT200500049A (es) | Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados | |
| HN2008001667A (es) | Antagonistas de los receptores cgrp espirociclicos sustituidos | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| DE602006019304D1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| MXPA05012894A (es) | Benzofuranos 3-sustituidos como agentes terapeuticos. | |
| ECSP066888A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| MY147347A (en) | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes | |
| RU2013145869A (ru) | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
| AR041942A1 (es) | Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| MXPA05012953A (es) | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. | |
| ATE538811T1 (de) | Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44 | |
| UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| CR9815A (es) | Compuestos de imidazol para el tratamiento de transtornos neurologicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |